Holen Sie sich die Stockscreener-App
0.1048
13.96%
-0.017
Handel nachbörslich:
.10
-0.0048
-4.58%
Schlusskurs vom Vortag:
$0.1218
Offen:
$0.1118
24-Stunden-Volumen:
56.39M
Relative Volume:
2.51
Marktkapitalisierung:
$9.06M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+31.66%
1M Leistung:
-38.10%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.0907
$0.1175
1-Wochen-Bereich:
$0.0651
$0.1695
52-Wochen-Spanne:
$0.0651
$2.22
Profusa Inc Stock (PFSA) Company Profile
Firmenname
Profusa Inc
Sektor
Branche
Telefon
212-494-9022
Adresse
207 WEST 25TH ST, 9TH FLOOR, NEW YORK
Vergleichen Sie PFSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
0.1048 | 10.53M | 0 | 0 | 0 | 0.00 |
|
ABT
Abbott Laboratories
|
125.29 | 218.72B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
95.35 | 142.33B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
351.47 | 135.42B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
96.06 | 123.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
85.25 | 50.02B | 5.88B | 1.34B | 799.60M | 2.3489 |
Profusa Inc Aktie (PFSA) Neueste Nachrichten
Profusa restructures senior secured convertible notes - MSN
Profusa expands European footprint with French distributor partnership By Investing.com - Investing.com Nigeria
Profusa expands European footprint with French distributor partnership - Investing.com India
Profusa Bolsters European Commercial Network with New French Distributor, MedSell - The Manila Times
New French deal brings oxygen monitoring tech to critical limb patients - Stock Titan
Profusa stock whipsaws: PFSA dips premarket after 78% surge on debt restructuring - ts2.tech
Nio, Profusa, Nike, FTAI Aviation And Under Armour: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Profusa Stock Soars—To 12 Cents—On Debt Restructuring - Benzinga
Profusa (PFSA) Stock: Announces Key Changes to Senior Secured Convertible Notes for Stronger Financial Health - parameter.io
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
Nasdaq Trading Activity: Profusa Leads High-Volume Movers on December 30, 2025News and Statistics - IndexBox
Here’s Why Profusa Stock (PFSA) Rocketed Today - TipRanks
Profusa Restructures Senior Secured Convertible Notes; Shares Jump Pre-Bell - marketscreener.com
Profusa restructures convertible note to reduce dilution, increase flexibility - Investing.com
Profusa amends securities purchase agreement to allow for $5 million note sale - Investing.com
Profusa restructures convertible note to reduce dilution, increase flexibility By Investing.com - Investing.com Australia
Profusa Signs Amendment No. 3 to Securities Purchase Agreement With Ascent Partners Fund - TradingView — Track All Markets
Profusa Restructures Senior Secured Convertible Notes, Only Convertible Above $0.35 - GlobeNewswire
Profusa amends equity deal and convertible note terms - MSN
Profusa amends securities agreements with Ascent Partners Fund By Investing.com - Investing.com Nigeria
Profusa Amends Equity Deal and Convertible Note Terms - TipRanks
Profusa amends securities agreements with Ascent Partners Fund - Investing.com
Profusa Updates Multiple Financing Agreements With Ascent Partners Fund - TradingView — Track All Markets
12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga
Profusa (NASDAQ:PFSA) versus ReShape Lifesciences (OTCMKTS:RSLSD) Financial Contrast - Defense World
Profusa’s Lumee oxygen monitoring meets key endpoints in PAD study By Investing.com - Investing.com Nigeria
Profusa’s Lumee oxygen monitoring meets key endpoints in PAD study - Investing.com
Profusa U.S. Study Met Primary End Points as Presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - The Manila Times
Profusa U.S. study met primary end points as presented at Late Breaking Clinical Trials at Paris Vascular Insights 2025 - marketscreener.com
Profusa U.S. Study Met Primary End Points As Presented At Late Breaking Clinical Trials At Paris Vascular Insights 2025 - TradingView — Track All Markets
Profusa (Nasdaq: PFSA) U.S. Lumee PAD study hits endpoints, backs potential FDA filing - Stock Titan
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Profusa to Present US-Study Clinical Data at Leipzig Interventional Course (LINC) 2026 - The Manila Times
Profusa (Nasdaq: PFSA) to share US pilot PAD Lumee data at LINC 2026 in Leipzig - Stock Titan
The growth track for Profusa Inc (PFSA) has changed recently - setenews.com
Profusa, Inc. Common Stock (PFSA) -5.4% in Intraday Trading: Decline Despite Positive Clinical Update - Stocks Telegraph
Q&A: Real-time digital healthcare for 2026 - Digital Journal
Top investors say TSS Inc (TSSI) ticks everything they need - Setenews
How does Profusa Inc (PFSA) change from a tortoise to a hare? - Setenews
Profusa to Present Late Breaking U.S. Based Clinical Trial Update at Paris Vascular Insights 2025 - marketscreener.com
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025 - The Manila Times
Profusa (Nasdaq: PFSA) to Share U.S. Lumee PAD Trial Update at PVI 2025 conference - Stock Titan
Profusa (PFSA) Competitors and Alternatives 2025 - MarketBeat
Profusa (PFSA) Stock Forecast and Price Target 2025 - MarketBeat
Profusa, Inc.Common Stock (NQ: PFSA - Markets Financial Content
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Profusa, Inc. (PFSA) -10.7% in Normal Trading: Decline Amid Recent Financial Update - Stocks Telegraph
Profusa raises USD 12M in gross proceeds from convertible PIPE note - Medical Buyer
Profusa Announces Q3 Highlights and Strategic Merger - TipRanks
Profusa, Inc. Announces Third Quarter 2025 Financial Results and Business Highlights - TradingView
Finanzdaten der Profusa Inc-Aktie (PFSA)
Es liegen keine Finanzdaten für Profusa Inc (PFSA) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):